The US market showcased steady market share gains in Lupin’s key drugs Albuterol and Levothyroxine. Product rationalisation has also helped in margin improvement.

Share Market Live

NSE

The US market which constitutes about 40 percent of sales, though the last few quarters were impacted, medium-term prospects for the company is bright. The company is expecting to clock 20 percent market share in Albuetrol by end of FY22.

The company’s operating margin is also likely to improve to 20-22 percent in the next 2 years.

In the special segment ‘Moneycontrol Pro Ideas For Profit’, moneycontrol’s Anubhav Sahu gets more details on the company’s performance.

Watch the video for more.

Disclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.

(Edited by : Aditi Gautam)

First Published:May 17, 2021 4:30 PM IST